Published on 25 May 2023
Description:
The pharmaverse is changing, evolving and innovating at supreme speed, and the magazine is here to capture this industry-wide revolution. In this edition we go big on the bold ambition of clinical trials - what is shaping them and the growing role of patients. Pharma Times also celebrates with a host of trail-blasers as the International Clinical Research of the Year Awards reach a jubilant climax.
Categories:
PharmaTimesPreview:
29 articles from this collection:
Cover
2 - FlyPharma Europe 2023
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: NHS
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-11 - CLINICAL TRIALS: Right time, right place – right research!
12 - CLINICAL TRIALS: A reflection of society
13 - CLINICAL TRIALS: Breaking boundaries
14 - ADVERTS
15-17 - INTCROY AWARDS: Chelsea roar
18 - YOUNG LEADERS: Shine a light
18 - PharmaRole
19 - FILM REVIEW: Still him
20-21 - NHS: Game changer…
22 - THOUGHT LEADERSHIP: Home truths
23 - Vienna Pharma Handling Center
24-25 - MEDICINES: Euro vision!
26-27 - COVID-19: Event horizon
28-29 - DIGITAL: Unlocking data’s destiny
30-31 - INDUSTRY: Drive time
32-33 - FUTURE: Spire-less technology?
34-35 - DIGITAL: Sight and sound
36-37 - Your moves
38 - AI: Age of AI
39 - USCROY
40 - COMMUNICATIONS AWRDS
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.